The article focuses on the way that the EU shapes the course of research and ADITEC is highlighted on its success of comparing different companies’ adjuvants due to a collaborative consortium across Europe and the US.
The European Union has dedicated more than €120 billion (almost 13%) of its 2014–20 budget to research and innovation (R&I). A host of other EU-funded programmes also support or are connected to R&I activities, but don’t define the amount of their investment.
ADITEC is highlighted as a project has already produced the first direct comparison of different companies’ ‘adjuvants’, substances that strengthen immune responses. “We had always thought it would be impossible to compare them” says ADITEC coordinator Rino Rappuoli. Read more.